An Open Label, Multi-center Safety and Tolerance Study of EP2101 Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer (NSCLC)
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
United States: Food and Drug Administration
EP2101-101
NCT00054899
January 2003
Name | Location |
---|---|
University of Washington | Seattle, Washington 98195 |
Mary Crowley Medical Research Center | Dallas, Texas 75246 |
Tyler Cancer Center | Tyler, Texas 75702 |
Cancer Care Northwest | Spokane, Washington 99202 |
Duke University Medical Center | Durham, North Carolina 27710 |
Cancer Centers of Florida | Orlando, Florida 32806 |
University of California, Los Angeles | Los Angeles, California |
New York Oncology Hematology | Albany, New York 12208 |